EGAGenomicsN/Ahttps://ega-archive.org/datasets/EGAD0000100632996EGA dataset EGAD00001006329EGAThe results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM). In this study, we performed gene expression profiling (DASL and RNA-seq) of formalin-fixed, paraffin-embedded tumor material from participants of the BELOB trial to identify patients with recurrent GBM who benefitted most from beva+CCNU treatment. We demonstrate that tumors assigned to the IGS-18 or "classical" subtype and treated with beva+CCNU showed a significant benefit in progression-free survival and a trend toward benefit in overall survival, whereas other subtypes did not exhibit such benefit. In particular, expression of FMO4 and OSBPL3 was associated with treatment response. Importantly, the improved outcome in the beva+CCNU treatment arm was not explained by an uneven distribution of prognostically favorable subtypes as all molecular glioma subtypes were evenly distributed along the different study arms. The RNA-seq analysis also highlighted genetic alterations, including mutations, gene fusions, and copy number changes, within this well-defined cohort of tumors that may serve as useful predictive or prognostic biomarkers of patient outcome. Further validation of the identified molecular markers may enable the future stratification of recurrent GBM patients into appropriate treatment regimens.Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.Erdem-Eraslan Lale L, van den Bent Martin J MJ, Hoogstrate Youri Y, Naz-Khan Hina H, Stubbs Andrew A, van der Spek Peter P, Böttcher René R, Gao Ya Y, de Wit Maurice M, Taal Walter W, Oosterkamp Hendrika M HM, Walenkamp Annemiek A, Beerepoot Laurens V LV, Hanse Monique C J MC, Buter Jan J, Honkoop Aafke H AH, van der Holt Bronno B, Vernhout René M RM, Sillevis Smitt Peter A E PA, Kros Johan M JM, French Pim J PJfalseena-DATASET-ErasmusMC-29-07-2020-09:33:21:184-2056 - samplesRNA-Seq samples from the BELOB clinical trial study to find transcriptome associations with response to Bevacizumab and CCNU in glioblastoma patients2021-07-05 08:18:27EGAD00001006329960626762204EGAC00001001686EGAS00001004570